ConductScience.org, home

Library / Genes

BTK: Bruton tyrosine kinase

1 protein, 108 patents, 24 drugs, 898 trials, 4,550 NIH grants and 13,552 papers.

Gene 7

Its symbol and name are HGNC's, unless HGNC and NCBI Gene contradict each other.

FieldValueSource
SymbolBTKHGNC
NameBruton tyrosine kinaseHGNC
NCBI Gene ID695NCBI Gene
HGNC IDHGNC:1133HGNC
EnsemblENSG00000010671NCBI Gene
AliasesAGMX1, AT, ATK, BPK, IGHD3, IMD1, PSCTK1, XLANCBI Gene
Typeprotein-codingNCBI Gene

Proteins 1

Reviewed human proteins whose Swiss-Prot entry states the gene.

UniProt entryProteinLengthStructuresGene stated inSource
Q06187Tyrosine-protein kinase BTK659161Ensembl, GeneID, HGNCUniProt

Patents 108

Patents whose sequence listing holds the protein exactly: the same sequence, by SHA-256, length and CRC-64. A sequence a patent lists is not always one it claims.

PublicationPublishedSEQ ID NOProteinSource
JP 2026511570 A2026-04-1431Q06187Espacenet
EP 4670728 A12025-12-3131Q06187Espacenet
KR 1020250166953 A2025-11-2831Q06187Espacenet
EP 4641201 A22025-10-294096Q06187Espacenet
EP 4641202 A22025-10-294828Q06187Espacenet
WO 2025215591 A12025-10-163Q06187Espacenet
JP 2025517969 A2025-06-124096Q06187Espacenet
JP 2025062604 A2025-04-149905Q06187Espacenet
US 12268666 B22025-04-081Q06187Espacenet
JP 2025037966 A2025-03-181Q06187Espacenet

Drugs 24

Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.

DrugChEMBL IDMechanismActionSource
ABIVERTINIBCHEMBL4297865Tyrosine-protein kinase BTK inhibitorINHIBITORChEMBL
ABIVERTINIB MALEATECHEMBL4297866Tyrosine-protein kinase BTK inhibitorINHIBITORChEMBL
ACALABRUTINIBCHEMBL3707348Tyrosine-protein kinase BTK inhibitorINHIBITORChEMBL
ACALABRUTINIB MALEATECHEMBL4594293Tyrosine-protein kinase BTK inhibitorINHIBITORChEMBL
BMS-986142CHEMBL3900554Tyrosine-protein kinase BTK inhibitorINHIBITORChEMBL
BRANEBRUTINIBCHEMBL4297674Tyrosine-protein kinase BTK inhibitorINHIBITORChEMBL
EDRALBRUTINIBCHEMBL4650338Tyrosine-protein kinase BTK inhibitorINHIBITORChEMBL
ELSUBRUTINIBCHEMBL4594348Tyrosine-protein kinase BTK inhibitorINHIBITORChEMBL
EVOBRUTINIBCHEMBL4072833Tyrosine-protein kinase BTK inhibitorINHIBITORChEMBL
FENEBRUTINIBCHEMBL4065122Tyrosine-protein kinase BTK inhibitorINHIBITORChEMBL

Trials 898

Trials of those drugs. A trial joins the gene only through a drug that acts on it.

TrialDrugPhaseResults first postedSource
NCT07604987PIRTOBRUTINIBPHASE2ClinicalTrials.gov
NCT07585747ORELABRUTINIBPHASE2ClinicalTrials.gov
NCT07582159ACALABRUTINIBPHASE2ClinicalTrials.gov
NCT07574073ORELABRUTINIBPHASE1ClinicalTrials.gov
NCT07554898ORELABRUTINIBPHASE2ClinicalTrials.gov
NCT07550855ZANUBRUTINIBPHASE2ClinicalTrials.gov
NCT07548450PIRTOBRUTINIBPHASE2ClinicalTrials.gov
NCT07548255ZANUBRUTINIBPHASE1ClinicalTrials.gov
NCT07516093PIRTOBRUTINIBPHASE3ClinicalTrials.gov
NCT07505849ZANUBRUTINIBPHASE2ClinicalTrials.gov

NIH grants 4550

NIH projects whose papers are about the gene, through NIH's grant-paper links.

ProjectTitleIts papers about the geneNewest fiscal yearSource
P30CA016672Cancer Center Support Grant2132,025NIH's project files
P30CA008748Cancer Center Support Grant1712,025NIH's project files
P30CA016058Cancer Center Support Grant822,025NIH's project files
ZIAHL002346Tumor microenvironment in CLL and MCL: pathogenesis, targets, and therapy592,025NIH's project files
P30CA021765Cancer Center Support Grant (CCSG)402,025NIH's project files
R01CA177292Targeted Therapies for Lymphoid Malignancies402,025NIH's project files
R01AI043957Structural Studies of a T cell Specific Tyrosine Kinase322,025NIH's project files
P30CA076292Moffitt Cancer Center Support Grant242,025NIH's project files
P01CA206978Comprehensive dissection of the CLL genome & phenome to improve patient outcomes212,025NIH's project files
K12CA133250OSU K12 Training Grant in Oncology192,025NIH's project files

Papers 13552

Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.

PMIDFound bySource
42827116PubTator, text miningPubMed
42825907PubTator, text miningPubMed
42825552PubTator, text miningPubMed
42822477PubTator, text miningPubMed
42821736PubTator, text miningPubMed
42819318PubTator, text miningPubMed
42817838PubTator, text miningPubMed
42814177PubTator, text miningPubMed
42812772PubTator, text miningPubMed
42810753PubTator, text miningPubMed

The same record as JSON

Release gene-search-2026-11-11-0.1.0

ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

ChEMBL, through Open Targets: CC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence

ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

EMBL-EBI's patent proteins: EMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use

GenBank's patent files: GenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/

HGNC: CC0: https://www.genenames.org/about/license/

NCBI Gene: None named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/

NIH's project files and grant-paper links: Public domain (NIH RePORTER)

Open Targets: CC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence

PubTator 3: Public domain

UniProt: CC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license